Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
Data presented at EASL Congress 2023
- alfapump was effective in the control of ascites, virtually eliminating needle paracentesis
- Safety in line with expectations – particularly given disease progression in these patients – six primary safety events and limited number of key secondary safety events
- Clinically meaningful and statistically significant improvement in patients’ quality of life
- One year survival of 70% compares favorably to literature in this patient population
Ghent, Belgium – 21 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces additional data on safety, quality of life and survival from POSEIDON, its North American pivotal study of alfapump for the treatment of patients with recurrent or refractory ascites due to liver cirrhosis. These data will be presented during a poster session today and have been selected for an oral poster presentation on June 23rd from 12:45 to 12:55 CEST at the EASL Congress in Vienna, Austria.
